Strategic Partnerships HALIX has recently partnered with AstraZeneca for COVID-19 vaccine development and manufacturing at clinical and commercial scales, and with RocketVax AG to bolster global pandemic preparedness. These collaborations indicate openness to tier-one biotech partnerships and potential opportunities to offer CDMO services for viral vaccines, viral vectors, and large-scale manufacturing projects.

Vaccine & Pandemic Focus With a track record in enabling vaccines and biopharmaceuticals against cancer, COVID-19, influenza, and other infectious diseases, HALIX is positioned to support customers pursuing complex biologics, viral vectors, and vaccine programs—areas where pharma companies may seek reliable, compliant manufacturing and development capabilities.

Leadership & Growth Recent leadership appointment of a new CEO along with ongoing expansions signals a growth trajectory and investment in strategic account management. This presents an opportunity to engage senior stakeholders, align on long-term CDMO partnerships, and present scalable manufacturing and development plans.

Global Capabilities HALIX supports pharmaceutical companies worldwide from GMP facilities in Leiden, indicating capability for international collaborations, technology transfer, and multi-site production programs. Potential sales angles include cross-border manufacturing routes, regulatory-compliant scale-up, and global supply continuity.

Technology & Compliance Investments in a robust tech stack and emphasis on quality, compliance, and sustainability point to a reliability-driven value proposition. Sales opportunities exist to emphasize integrated IT-enabled batch tracking, secure data management, and audit-ready operations for regulated biologics programs.